Details of the Drug

General Information of Drug (ID: DMFJZN0)

Drug Name

Romosozumab

Synonyms

AMG 785

Indication

Disease Entry	ICD 11	Status	REF
Postmenopausal osteoporosis	FB83.11	Approved	[1]
------------------------------------------------------------------------------------

Drug Type

Antibody

ADMET Property

Clearance: The clearance of drug is 0.38 mL/h/kg [2]
Half-life: The concentration or amount of drug in body reduced by one-half in 12.8 days [2]
Vd: The volume of distribution (Vd) of drug is 3.92 L [2]

Cross-matching ID

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

Molecular Interaction Atlas (MIA)

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Postmenopausal osteoporosis

ICD Disease Classification

FB83.11

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Sclerostin (SOST)	DTT	SOST	1.11E-01	0.9	2.87

Molecular Expression Atlas (MEA)

Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Romosozumab (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Etelcalcetide	DMHP9BL	Major	Increased risk of hypocalcemia by the combination of Romosozumab and Etelcalcetide.	Hyper-parathyroidism [5A51]	[3]
-----------

References

1	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
2	FDA Approved Drug Products: EVENITY (romosozumab-aqqg) injection, for subcutaneous use
3	Cerner Multum, Inc. "UK Summary of Product Characteristics.".